{
  "trial_id": "NCT00367627",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "age",
      "label": "met",
      "evidence": "35 years old"
    },
    {
      "criterion": "myasthenia gravis",
      "label": "met",
      "evidence": "class IIa, positive anti-AChR antibody test, single fiber electromyography (SFEMG) was positive"
    },
    {
      "criterion": "diplopia and fatigue and weakness",
      "label": "met",
      "evidence": "mainly her upper limbs"
    },
    {
      "criterion": "pyridostigmine 60 mg three times a day",
      "label": "met",
      "evidence": "takes pyridostigmine"
    }
  ],
  "exclusion": [
    {
      "criterion": "age",
      "label": "not_met",
      "evidence": "35 years old"
    },
    {
      "criterion": "serious chronic illness",
      "label": "unknown",
      "evidence": "has some symptoms that interfere with her job"
    },
    {
      "criterion": "parents/guardian are not willing to give consent",
      "label": "unknown",
      "evidence": "no mention of parents/guardian unwillingness"
    }
  ],
  "notes": "35-year-old woman with myasthenia gravis, class IIa. She complains of diplopia and fatigue and weakness that affects mainly her upper limbs.",
  "_meta": {
    "topic_id": "38",
    "trial_id": "NCT00367627",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}